EVOSEP ESTABLISHES CENTER OF EXCELLENCE FOR HIGH-THROUGHPUT AND STANDARDIZED PROTEOMICS
Chicago, USA – Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics. We will make sample preparation and separation for MS analysis 10 times faster and 100 times more robust in order to enable truly large cohort studies and provide the foundation for precision medicine.
Therefore, we are establishing Evosep Biolabs as a center of excellence for high throughput proteomics to demonstrate the power of automated sample preparation and standardized separation methods. Evosep Biolabs will partner with key players in the proteomics area, execute end-to-end workflows on customer projects, remove barriers to entry by acting as an external, expert lab partner, as well as providing extra, ad-hoc capacity to established organizations.
Initially based in Odense, Denmark, Evosep Biolabs is planning to open an additional combined office and lab facility in Boston, USA in the immediate future.
Scaling up experiments
Proteomics is going through a significant paradigm shift and is rapidly evolving towards higher throughput and robust easier-to-use technologies.
This has shifted the bottleneck for realizing high-throughput proteomics towards sample preparation, creating a need for rapid, robust, and reproducible end-to-end automated workflows.
Enabling high throughput
Proteomics is also a very specialized field with high requirements to skills, expertise, and technical platforms, all of which can be very time consuming and costly to establish from scratch.
The Evosep One integrates seamlessly with liquid handlers and all the relevant mass spectrometers necessary for proteomics analysis, and Evosep Biolabs can demonstrate this on small sample sets and large cohorts alike.
Generating new insights
Analyzing large scale proteomics samples can provide valuable insights into biological systems, disease biomarkers, post-translational modifications, as well as open up for integration with other omics data for e.g. developing new drugs and therapies.
Dr. Ole Vorm, Founder and Chairman of Evosep, envisions that: “Precision medicine is set to revolutionize healthcare in the coming decade or two. And precision diagnostics is a crucial first step to getting there. The Evosep One was engineered for robust and fast clinical proteomics and we are now very excited to accelerate our efforts towards clinical proteomics”.
For more information, please call +45 2633 2021, e-mail [email protected], or visit www.evosep.com.
Evosep aims to improve quality of life and patient care by radically innovating protein based clinical diagnostics, initially through collaborations with world-leading scientists about developing new technologies and solutions to make sample separation 100 times more robust and 10 times faster than todays’ alternatives. Information about Evosep is available at www.evosep.com.
The Evosep One instrument is for Research Use Only (RUO).
Media Contact Information: